Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nike
NKE
5
Palantir
PLTR
HK Stock MarketDetailed Quotes
01177 SINO BIOPHARM
- 3.890
- -0.060-1.52%
Market Closed Apr 3 16:08 CST
73.01BMarket Cap19.35P/E (TTM)
3.980High3.810Low137.70MVolume3.910Open3.950Pre Close532.77MTurnover0.73%Turnover Ratio19.35P/E (Static)18.77BShares4.25052wk High2.12P/B73.01BFloat Cap2.23052wk Low0.06Dividend TTM18.77BShs Float10.900Historical High0.050Dividend LFY4.30%Amplitude-0.677Historical Low3.869Avg Price1000Lot Size1.54%Div YieldTTM1.29%Div Yield LFY
SINO BIOPHARM Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (Q3)Mar 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 10.18%28.87B | 11.14%15.87B | 0.67%26.2B | -5.99%14.28B | -3.11%26.03B | 5.85%15.19B | 13.59%26.86B | 13.49%14.35B | 16.41%7.24B | -2.42%23.65B |
| Operating income | 10.18%28.87B | 11.14%15.87B | 0.67%26.2B | -5.99%14.28B | -3.11%26.03B | 5.85%15.19B | 13.59%26.86B | 13.49%14.35B | 16.41%7.24B | -2.42%23.65B |
| Cost of sales | -6.94%-5.34B | -9.42%-2.84B | -11.19%-4.99B | 12.16%-2.6B | 15.84%-4.49B | -7.50%-2.96B | -2.89%-5.33B | 1.39%-2.75B | -11.75%-1.42B | -5.20%-5.18B |
| Operating expenses | -6.94%-5.34B | -9.42%-2.84B | -11.19%-4.99B | 12.16%-2.6B | 15.84%-4.49B | -7.50%-2.96B | -2.89%-5.33B | 1.39%-2.75B | -11.75%-1.42B | -5.20%-5.18B |
| Gross profit | 10.94%23.53B | 11.52%13.03B | -1.53%21.21B | -4.50%11.68B | 0.04%21.54B | 5.46%12.23B | 16.60%21.53B | 17.70%11.6B | 17.60%5.83B | -4.37%18.46B |
| Selling expenses | -9.62%-10.08B | -11.03%-5.8B | 6.28%-9.19B | 9.23%-5.22B | 6.74%-9.81B | -1.52%-5.75B | -17.23%-10.52B | -22.83%-5.67B | -22.58%-3.05B | 3.72%-8.97B |
| Administrative expenses | -11.12%-2.08B | -4.58%-1.05B | 1.38%-1.87B | 14.99%-1.01B | 13.08%-1.9B | -4.97%-1.18B | 17.72%-2.19B | -6.90%-1.13B | 4.41%-448.06M | -7.21%-2.66B |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | -14.98%-169.27M | 4.56%-308.62M | 15.55%-147.22M | ---71.66M | -40.63%-323.37M |
| Special items of operating profit | -51.07%-6.18B | -22.74%-2.32B | -1.44%-4.09B | -0.61%-1.89B | -12.79%-4.03B | -48.22%-1.88B | -138.87%-3.58B | 7.01%-1.27B | -38.40%-889.49M | 12.04%-1.5B |
| Operating profit | -14.23%5.19B | 8.24%3.86B | 4.40%6.05B | 9.70%3.57B | 17.31%5.8B | -4.19%3.25B | -1.48%4.94B | 27.98%3.39B | 0.89%1.36B | -10.09%5.02B |
| Financing income | 32.04%499.56M | ---- | --378.34M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Financing cost | 40.41%-295.12M | 47.61%-153.74M | -15.31%-495.24M | ---293.43M | ---429.49M | ---- | ---- | ---- | ---- | ---- |
| Share of profits of associates | 77.50%-118.3M | 57.59%-93.06M | -243.66%-525.71M | -143.61%-219.44M | -101.12%-152.98M | -93.37%503.16M | 421,714.29%13.63B | 18,515.51%7.58B | 59,124.43%1.48B | -102.90%-3.23M |
| Earning before tax | -2.45%5.28B | 18.33%3.61B | 3.74%5.41B | -18.66%3.05B | -71.92%5.21B | -65.80%3.75B | 270.49%18.57B | 320.56%10.98B | 124.63%2.84B | -11.91%5.01B |
| Tax | 38.17%-492.92M | -23.31%-614.09M | -14.43%-797.27M | 12.85%-497.99M | 64.41%-696.72M | 57.26%-571.39M | -191.19%-1.96B | -144.71%-1.34B | -110.57%-446.94M | 25.52%-672.38M |
| After-tax profit from continuing operations | 3.73%4.78B | 17.36%3B | 2.09%4.61B | -19.70%2.56B | -72.81%4.52B | -66.98%3.18B | 282.77%16.61B | 367.10%9.64B | 127.46%2.39B | -9.34%4.34B |
| After-tax profit from non-continuing business | 225.96%1.58B | 1,021.31%1.61B | 0.06%484.76M | --143.29M | --484.47M | ---- | ---- | ---- | ---- | ---- |
| Earning after tax | 24.86%6.36B | 70.65%4.61B | 1.89%5.1B | -15.20%2.7B | -69.89%5B | -66.98%3.18B | 282.77%16.61B | 367.10%9.64B | 127.46%2.39B | -9.34%4.34B |
| Minority profit | 3.59%2.86B | 10.33%1.59B | 12.46%2.77B | 14.14%1.44B | 22.56%2.46B | 8.69%1.26B | 27.83%2.01B | 41.01%1.16B | 152.26%480.92M | -22.54%1.57B |
| Profit attributable to shareholders | 50.08%3.5B | 139.69%3.02B | -8.32%2.33B | -34.47%1.26B | -82.59%2.54B | -77.35%1.92B | 427.17%14.61B | 583.56%8.48B | 121.98%1.91B | 0.35%2.77B |
| Basic earnings per share | 51.95%0.1913 | 141.74%0.1639 | -7.83%0.1259 | -34.17%0.0678 | -82.45%0.1366 | -77.19%0.103 | 428.02%0.7783 | 584.09%0.4515 | 48.76%0.1019 | 0.41%0.1474 |
| Diluted earnings per share | 51.95%0.1913 | 141.74%0.1639 | 3.62%0.1259 | -26.30%0.0678 | -83.42%0.1215 | -78.79%0.092 | 397.01%0.7326 | 557.27%0.4338 | 35.47%0.0928 | 0.41%0.1474 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | Unqualified Opinion |
| Auditor | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.